APA (7th ed.) Citation

Petrera, M., Scherer, D., Haefeli, W. E., & Ulrich, C. (2018). The ASAMET trial: A randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients. BioMed Central ; Springer. https://doi.org/https://doi.org/10.1186/s12885-018-5126-7

Chicago Style (17th ed.) Citation

Petrera, Marilena, Dominique Scherer, Walter E. Haefeli, and Cornelia Ulrich. The ASAMET Trial: A Randomized, Phase II, Double-blind, Placebo-controlled, Multicenter, 2 × 2 Factorial Biomarker Study of Tertiary Prevention with Low-dose Aspirin and Metformin in Stage I-III Colorectal Cancer Patients. London Berlin, Heidelberg: BioMed Central ; Springer, 2018. https://doi.org/https://doi.org/10.1186/s12885-018-5126-7.

MLA (9th ed.) Citation

Petrera, Marilena, et al. The ASAMET Trial: A Randomized, Phase II, Double-blind, Placebo-controlled, Multicenter, 2 × 2 Factorial Biomarker Study of Tertiary Prevention with Low-dose Aspirin and Metformin in Stage I-III Colorectal Cancer Patients. BioMed Central ; Springer, 2018. https://doi.org/https://doi.org/10.1186/s12885-018-5126-7.